Adicet bio reports inducement grant under nasdaq listing rule 5635(c)(4)

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for cancer, today announced it granted an inducement award on december 29, 2023. one individual was hired by adicet in december 2023 and granted new hire non-qualified stock options to purchase 84,000 shares of adicet's common stock with an exercise price of $1.89 per share, the closing price of adicet's common.
ACET Ratings Summary
ACET Quant Ranking